http://www.fpnotebook.com/
VecuroniumAka: Norcuron
- See Also
- Precautions
- Used only in anesthesia, emergency and intensive care
- Airway and respiratory control is critical after use
- Paralytic Agents do not alter Level of Consciousness
- Must be used with Sedation and analgesia
- Indication
- Paralysis in Rapid Sequence Intubation
- Mechanism
- Non-depolarizing Neuromuscular Blocking Agent
- Structurally similar to Pancuronium
- Same steroid nucleus
- Tertiary Nitrogen at position 2 is only difference
- Significantly different effects than Pancuronium
- Duration of action is half that of Pancuronium
- Hepatic excretion predominates
- Minimal cardiovascular effects
- Dose
- Initial Dose
- Vecuronium alone: 0.08 to 0.1 mg/kg IV
- Vecuronium after Succinylcholine: 0.04 to 0.06 mg/kg
- Maintenance dosing (if needed)
- Starts 25-40 minutes after initial dose
- Please see other references for maintenance dosing
- Reduce dosage in hepatic Impairment
- Do not use by intramuscular dosing
- Initial Dose
- Pharmacokinetics
- Onset: 1-2 minutes
- Maximal Neuromuscular Blockade by 3-5 minutes
- Duration: 30 minutes
- References
- Miller in Katzung (1989) Pharmacology, p. 323-33
- Savarese in Miller (2000) Anesthesia, p. 412-90
- (2003) Lexicomp Drug database for Pocket PC
Vecuronium (C0242531) | |
|---|---|
| Concepts | Steroid (T110) , Pharmacologic Substance (T121) |
| MSH | D014673 |
| English | Vecuronium, VECURONIUM PREPARATION |
| Spanish | vecuronio |
| Parent Concepts | Neuromuscular Blocking Agents (C0027866), Nondepolarizing agent (C0304435), Steroidal neuromuscular blocker (C1631057), Skeletal Muscle Relaxants (C0037250) |
| Sources | LNC, MSH, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Norcuron (C0700018) | |
|---|---|
| Concepts | Steroid (T110) , Pharmacologic Substance (T121) |
| MSH | D014673 |
| English | Norcuron |
| Sources | MSH, NCI, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
